Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

This study is currently recruiting participants.
Verified October 2013 by Medical University of Vienna
Sponsor:
Information provided by (Responsible Party):
Lukas Pezawas, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01251471
First received: December 1, 2010
Last updated: October 16, 2013
Last verified: October 2013

December 1, 2010
October 16, 2013
August 2011
October 2014   (final data collection date for primary outcome measure)
BOLD signal [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01251471 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response
Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

The aim of this pharmaco-MRI study is to investigate neural correlates of variable antidepressant treatment response driven by genetic variation in multiple genes involved in depression.

Thirty Major Depressive Disorder (MDD) patients with a concurrent major depressive episode will undergo three MRI scanning sessions after escitalopram treatment initiation. Furthermore, extensive behavioral assessments and measures of potential peripheral markers such lymphocyte mRNA or pharmacological parameters on platelets or lymphocytes will be performed.

Imaging measures have been suggested to be superior for drug response assessment as compared to psychometric scales, which hardly correlate with biological parameters. Since imaging techniques are too expensive and sophisticated for a broad clinical use, this study will provide pilot data on potential peripheral biomarkers of neural activation being related to drug response.

The aim of this pharmaco-MRI study is to investigate neural correlates of variable antidepressant treatment response driven by genetic variation in multiple genes involved in depression.

Thirty Major Depressive Disorder (MDD) patients with a concurrent major depressive episode will undergo three MRI scanning sessions at baseline, 4 hours and 8 weeks after escitalopram treatment initiation. During each MRI session, one structural and 3 fMRI scans each engaging different brain circuitries will be performed. All subjects will undergo extensive behavioral assessment and will be genotyped. Furthermore, potential peripheral markers such lymphocyte mRNA or pharmacological parameters on platelets or lymphocytes will be assessed.

The investigators expect that genetic variants which have been associated with variable response to SSRIs in previous Imaging Genetics studies are modulating neural targets of drug response. Moreover, peripheral markers are expected to correlate with these brain region measurements.

Imaging measures have been suggested to be superior for drug response assessment as compared to psychometric scales, which hardly correlate with biological parameters. Since imaging techniques are too expensive and sophisticated for a broad clinical use, this study will provide pilot data on peripheral biomarkers of neural activation being related to drug response. Furthermore, this study will demonstrate whether and how genotypes impact on the dynamics of neural drug response in vivo.

Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Depression
Drug: Escitalopram
10 mg/d; optional 20 mg/d after 2 weeks.
Other Names:
  • Lexapro
  • Cipralex
  • Seroplex
  • Lexamil
Experimental: Escitalopram
Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
Intervention: Drug: Escitalopram

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female
  • Age 18 -45 years
  • Right-handedness
  • DSM-IV diagnosis of a major depressive episode (SCID)
  • a MADRS score ≥20 and ≤ 30
  • ability to be managed as outpatients
  • ability to fulfill the criteria to undergo an MRI scan
  • Caucasian subjects of European ancestry

Exclusion Criteria:

  • previous or concurrent major medical or neurological illness
  • clinically significant abnormal values in routine laboratory screening or general physical examination
  • DSM-IV diagnosis of substance dependence within the past year, except for caffeine or nicotine or current substance abuse
  • DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or an anxiety disorder as a primary diagnosis
  • the use of any psychotropic drug within the last two months unresponsiveness of a former major depressive episode to an adequate antidepressive drug dosing of at least 6 weeks duration or any kind of therapy resistance
  • a history of severe drug allergy or hypersensitivity or known hypersensitivity to escitalopram
  • being acutely suicidal either indicated by a score ≥ 5 on item 10 (suicidal thoughts) on the MADRS or a score ≥ 4 on the HAM-D 21 (suicidal thoughts) or according to the investigator´s opinion
  • failures to comply with the study protocol or to follow the instructions of the investigating team
  • current pregnancy or breast feeding
  • metallic implants or other contraindications to MRI
Both
18 Years to 45 Years
No
Contact: Lukas Pezawas, MD 00431404003568 lukas.pezawas@meduniwien.ac.at
Austria
 
NCT01251471
OENB-13903
Yes
Lukas Pezawas, Medical University of Vienna
Medical University of Vienna
Not Provided
Principal Investigator: Lukas Pezawas, MD Medical University of Vienna, Dept. of Psychiatry and Psychotherapy
Medical University of Vienna
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP